The European Commission has opened an in-depth state aid investigation into Agrarmarkt Austria’s marketing measures. Agrarmarkt is a public body controlled by the Austrian state. It oversees the use of quality and organic labels, and its subsidiary AMA Marketing implements promotional measures for the AMA’s activities. The Commission believes that the marketing from 1995 and 2008 may be illegal state aid, as well as the financing of the marketing.
In 2002, internal directives on AMA labels changed. The Commission had previously found that AMA measures after the change in directives substantially complied with state aid rules. However, on appeal, the General Court held that the Commission should have opened a formal investigation “because of the existence of a contradiction between (i) the wording of the basic AMA Act and (ii) the new internal AMA directives and the assurances provided by Austrian authorities.” The current investigation will address the Court’s concerns.
Full content: EC Press Release
Related content: Some Reflections on the European Commission’s State Aid Policy (Philip Lowe, European Commission)
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Top Antitrust Expert Joins Cravath from Paul Weiss
Jan 21, 2025 by
CPI
CMA Chief Removed as UK Government Targets Regulatory Overhaul
Jan 21, 2025 by
CPI
Court Denies Dismissal in Crab Price-Fixing Lawsuit
Jan 21, 2025 by
CPI
TikTok Stays Online for Now: Trump Floats US Ownership Deal
Jan 21, 2025 by
CPI
Hong Kong Watchdog Unveils Compliance Tool for Small Businesses
Jan 21, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Pharmacy Benefit Managers
Jan 20, 2025 by
CPI
Untangling the PBM Mess
Jan 20, 2025 by
Kent Bernard
Using Data, Not Anecdotes, to Analyze Criticisms of Pharmacy Benefit Managers
Jan 20, 2025 by
Dennis Carlton
Vertical Integration and PBMs: What, Me Worry?
Jan 20, 2025 by
Lawton Robert Burns & Bradley Fluegel
The Economics of Benefit Management in Prescription-Drug Markets
Jan 20, 2025 by
Casey B. Mulligan